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Abstract
Background: Multidrug resistance (MDR) is frequently observed after prolonged treatment in
human hepatoma with conventional anti-tumor drugs, and photodynamic therapy (PDT) is a
recently suggested alternative to overcome MDR. The therapeutic potential of PDT was evaluated
in a multidrug resistance (MDR) human hepatoma cell line R-HepG2 with photosensitizer
pheophorbide a (Pa).
Results: Our results demonstrated that intracellular accumulation of Pa was not reduced by the
overexpression of P-glycoprotein. Pa-based PDT (Pa-PDT) significantly inhibited the growth of R-
HepG2 cells with an IC50 value of 0.6 μM. Mechanistic study demonstrated that genomic DNA
fragmentation and phosphatidylserine externalization occurred where increase of intracellular
singlet oxygen level triggers the phosphorylation of c-Jun N-terminal Kinase (JNK) and leads to
activation of intrinsic apoptotic caspases cascade during the Pa-PDT treatment. The cytotoxicity of
Pa-PDT, accumulation of sub-G1 population, and depolarization of mitochondrial membrane could
be inhibited by JNK inhibitor in the Pa-PDT treated cells. Interestingly, the Pa-PDT induced JNK
activation showed inhibitory effect on MDR by the down-regulation of P-glycoprotein in R-HepG2
cells in a dose-dependent manner. In addition, significant reduction of tumor size was obtained in
Pa-PDT treated R-HepG2-bearing nude mice with no significant damages in liver and heart.
Conclusion: In summary, our findings provided the first evidence that PDT could inhibit the MDR
activity by down-regulating the expression of P-glycoprotein via JNK activation using pheophorbide
a as the photosensitizer, and our work proved that Pa-PDT inhibited the growth of MDR hepatoma
cells by mitochondrial-mediated apoptosis induction.
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Introduction
Photodynamic therapy (PDT) was applied to treat dis-
eases such as psoriasis, rickets, vitiligo and skin cancer
thousand of years ago by ancient Egyptian, Indian and
Chinese [1-3]. PDT requires the presence of two non-toxic
elements: photosensitizer and light irradiation. When
they are applied together, a rapid intracellular stress is
generated in target tissues. Photosensitizers usually pro-
duce reactive oxygen species (ROS) after receiving light
energy during illumination in an oxygen-rich environ-
ment, and eventually initiate apoptosis or necrosis in the
treated cells [4]. Recently, PDT has been proposed as an
alternative to overcome multidrug resistance (MDR) for
anti-cancer treatment [5].
MDR is a situation that cancer cells are able to evade the
cytotoxic effects of a broad range of anti-tumor agents.
Expression of ATP-dependent membrane transporter P-
glycoprotein to pump drugs out of the cells is a common
phenomenon in tumor cells with MDR phenotypes [6].
MDR frequently appeared in liver cancer patients after
prolonged systemic treatment with anti-tumor drugs. For
example, low response rates (15 to 20%) were found in
hepatoma cases using doxorubicin (Dox) as an anti-can-
cer drug [7]. Furthermore, as P-glycoprotein in MDR
tumor cells can pump out a broad range of structurally
and functionally unrelated anti-cancer agents, it is diffi-
cult to treat MDR cancer patients by chemotherapy [8].
Hepatoma is one of the most common malignancies,
which contributes approximately 5 to 10% of all cancer
cases worldwide and nearly 1 million deaths annually.
However, no adjuvant or palliative treatment modalities
have been conclusively shown to prolong the survival of
patients suffering from hepatocellular carcinoma [7].
Liver cirrhosis is a common cause of hepatoma and it is
difficult for the surgical resection to treat hepatoma devel-
oping from this cause, accounting for less than 18% of
this type of patients. Thus, local ablation, intra-arterial
and systemic treatments are major therapeutic modalities
for hepatoma [9]. Therefore, development of new agents
with mild side effects and capability to circumvent the
MDR in hepatoma cells is an urgent need.
Pheophorbide a (Pa), a derivative of chlorophyll a, is an
active component from an ethnopharmacological herb
Scutellaria barbata in China. In previous study, it was
shown to exhibit anti-tumor effect on human lung and
liver cancers cells [10,11]. Furthermore, we have demon-
strated the anti-cancer effects of Pa mediated PDT (Pa-
PDT) in human hepatoma and uterine sarcoma cells
[12,13]. Meanwhile, its inhibitory effect was also reported
in a number of other human cancer cells, such as Jurkat
leukemia, pigmented melanoma, colonic cancer and pan-
creatic carcinoma [14-17].
Although PDT has been suggested in a number of studies
as an alternative treatment to overcome MDR [18-23], the
approach of Pa-PDT has not yet been evaluated systemat-
ically in any human cancer cell model carrying MDR. In
this study, we examined the effect of Pa-PDT on cytotoxic-
ity in human hepatoma cells with MDR, namely R-HepG2
cells. Our results demonstrated that Pa-PDT not only
induces mitochondrial-mediated apoptosis, but also
inhibits MDR by down-regulation of P-glycoprotein activ-
ity and expression in R-HepG2 cells.
Results
Pa-PDT circumvents drug resistance of R-HepG2 cells
The therapeutic potential of Pa-PDT on MDR was demon-
strated on multidrug resistant hepatocellular carcinoma
human cell line R-HepG2. The fluorescence of Pa and P-
glycoprotein substrate Dox in HepG2 and R-HepG2 cells
were semi-quantified under fluorescence microscope.
Strong fluorescence from Pa was shown in the cytosol of
both Pa-treated HepG2 and R-HepG2 cells, whereas
strong Dox fluorescence was observed only in HepG2 but
not R-HepG2 cells (Figure 1A). Furthermore, the cell via-
bilities decreased in a dose-dependent manner of Pa-PDT
with IC50 value of 0.6 μM in R-HepG2 cells (Figure 1B)
and 0.4 μM in HepG2 cells (data not shown) after 24 h.
When light illumination was absent, no toxic effect was
observed in the R-HepG2 cells treated with Pa only up to
a concentration of 2.5 μM (Figure 1B). Our findings sug-
gest that Pa is a potential agent to kill human hepatoma
cells even when they have developed MDR.
Pa-PDT inhibits the growth of R-HepG2 hepatoma 
xenograft tumor
The therapeutic potential of Pa-PDT on MDR cancer cells
was further confirmed with an animal model. The sizes of
R-HepG2 tumor in nude mice were monitored after Pa-
PDT treatment. As shown in Figure 1C, Pa-PDT (300 μg/
kg, s.c.) significantly (p < 0.05) inhibited the growth of R-
HepG2 cells, and the tumor size was reduced from
158.60% (control group) to 29.65% (Pa-PDT treated
group) 10 days after light illumination. In addition, no
significant increase in the tissue specific enzyme activities
of liver (ALT, AST) and heart (LDH) in the blood samples
of the Pa-PDT treated mice was observed when compared
to those of the control group suggesting that damages of
liver and heart were not observed after Pa-PDT treatment
(Figure 1D). We also observed that intraveneous injection
(i.v.) of Pa followed by PDT also did not cause any side
effects in these mice (results not shown).
Pa-PDT induces apoptosis in R-HepG2 cells
The proliferation of tumor cells under chemotherapy can
be suppressed by several mechanisms, such as cell cycle
arrest, necrosis and apoptosis. In order to determine the
underlying mechanism of Pa-PDT, nucleosomal DNAMolecular Cancer 2009, 8:56 http://www.molecular-cancer.com/content/8/1/56
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fragmentation was analyzed in R-HepG2 cells with or
without the treatment. As shown in Figure 2A, a typical
DNA ladder was observed for the 0.6 μM Pa-PDT treated
cells. However, no such DNA fragmentation was found in
the solvent control with light illumination or samples
with Pa but no light illumination (Figure 2A). In order to
confirm cell death process, detection of externalization of
PS and loss of membrane integrity in R-HepG2 cells were
performed. As shown in Figure 2B, 9.8% and 38.3% of
early apoptotic cells (annexin V-FITC positive and PI neg-
ative) were found in R-HepG2 cells treated with 0.6 μM or
0.8 μM Pa respectively, compared to 1.3% in the control
sample. The cell population with late phase of apoptosis
(annexin V-FITC positive and PI positive) also increased
Pa-PDT circumvents MDR on resistant human hepatoma cells R-HepG2 Figure 1
Pa-PDT circumvents MDR on resistant human hepatoma cells R-HepG2. (A) Intracellular accumulations of Pa and 
Dox in HepG2 and R-HepG2 cells. Cells (3 × 105/well) were incubated with Pa (2 μM) or Dox (2 μM) for 4 h, and then washed 
with PBS for 3 times. Fluorescence micrographs were acquired with an excitation wavelength at 400–440 nm and an emission 
wavelength at 590–650 nm under a Nikon TE2000 fluorescence microscope. Images are representative results of 3 independ-
ent experiments. Bar: 50 μm. (B) In vitro cytotoxicity of Pa-PDT in R-HepG2 cells. Cells (1 × 104/well) were incubated with 
increasing concentrations of Pa in a 96-well plate for 2 h and exposed to light illumination (84 J/cm2) for 20 min and subse-
quently incubated at 37°C, 5% CO2. For the control group, cells were treated with Pa only without light illumination. Cell sur-
vival was then assessed by MTT assay 24 h after treatment. Results are mean ± SD of three independent experiments. (C) In 
vivo study of Pa-PDT in R-HepG2 cells bearing mice. R-HepG2 cells (1 × 107) were injected into nude mice subcutaneously at 
day-7. At day 0, 8 nude mice in groups were treated with Pa (300 μg/kg) and photo-activation (30 min) was applied only once 
to the treatment group 24 h after the Pa pre-treatment. At day ten, the tumor size of each mouse was measured after the Pa-
PDT treatment and the data was expressed as mean ± S.D. (n = 8, * p value < 0.05). (D) Tissue damages in Pa-PDT treated 
mice were assessed by an increase in the leakage of tissue specific enzymes (LDH for heart, and AST and ALT for liver) to the 
blood. The specific enzyme activities of the blood samples of the tested mice were measured and expressed as the mean ± S.D. 
(n = 8, * p value < 0.05).
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Pa-PDT induces apoptosis in R-HepG2 cells Figure 2
Pa-PDT induces apoptosis in R-HepG2 cells. (A) DNA fragmentation was revealed by agarose gel electrophoresis. The 
cells (2 × 106/plate) were collected at 24 h after the treatment, Lane 1: solvent control (0.04% ethanol with light illumination); 
lane 2: cells treated with Pa (0.6 μM) without light illumination; lane 3: cells treated with Pa (0.6 μM) with 20 min light illumina-
tion (84 J/cm2); and lane M: DNA markers (100 base pair). (B) For the annexin V/PI assay, the Pa-PDT treated cells were col-
lected at 2 h and then stained with annexin V-FITC and PI (15 min) for apoptosis study. Results shown are representative of 3 
independent experiments.
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from 1.7% to 9.1% and 33.6% after the treatment with Pa
at 0.6 and 0.8 μM respectively. Our results therefore sug-
gest that Pa-PDT treatment would trigger cell death via
apoptosis in the R-HepG2 cells.
Pa-PDT activates apoptosis via JNK-mediated pathway in 
R-HepG2 cells
Singlet oxygen may be released from Pa-PDT-mediated
damaged mitochondria [13]. Actually, the intracellular
singlet oxygen level was increased in a dose-dependent
manner in R-HepG2 cells immediately after Pa-PDT treat-
ment (Figure 3A). As shown in Figure 3B, the cytotoxicity
of Pa-PDT was inhibited in the R-HepG2 cells when the
cells were pre-treated with JNK inhibitor, where the cell
viabilities could be restored to 80.5% and 48.5% in the
0.75  μM and 1.0 μM Pa-PDT treated R-HepG2 cells
respectively. The reversal effect of the JNK inhibitor was
quantified by PI-staining, the flow cytometric results show
that cells from sub-G1 phase accounted for 15.1% and
49.6% of the total cell population with 0.6 μM and 0.8
μM Pa-PDT at 24 h respectively, as compared to 1.5% in
the solvent control (Figure 3C). In contrast, no significant
Pa-PDT triggers JNK-dependent apoptotic pathway in R-HepG2 cells Figure 3
Pa-PDT triggers JNK-dependent apoptotic pathway in R-HepG2 cells. (A) Intracellular singlet oxygen generation. 
Cells (2 × 104/well) were treated with various concentrations of Pa-PDT, then the treated cells were stained with 10 μM trans-
1-(2'-methoxyvinyl) pyrene at 10 min after the PDT for 15 min in dark. The intensity of fluorescence was detected with a plate 
reader; the results shown are representative as mean ± S.D. of 3 independent experiments (* p value < 0.005). (B) Involve-
ment of JNK in the Pa-PDT induced cell death pathway. Cells (1 × 104/well) were co-incubated with increasing concentrations 
of Pa and 0.5 μM JNK inhibitor in a 96-well plate for 2 h and then treated with PDT, and subsequently incubated at 37°C, 5% 
CO2. Cell viability was then assessed by MTT assay 24 h after treatment. Results are mean ± SD of three experiments (* p 
value < 0.005). (C) For cell cycle analysis, cells with Pa or co-incubated with 0.6 μM Pa and 0.5 μM JNK inhibitor were har-
vested at 24 h after PDT treatment, fixed and stained with PI (10 μg/ml, 30 min). The stained cells were analyzed by flow 
cytometry, and the percentage of cell population in subG1, G0/G1, S and G2/M phase were shown in the table as mean ± SD 
of three independent experiments.
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increase in sub-G1 population was observed in the Pa-
PDT treated cells co-incubated with JNK inhibitor. It
showed an induction of G2/M phase arrest instead (Figure
3C). Therefore, a dose-dependent effect was found in R-
HepG2 cells after Pa-PDT treatment.
Pa-PDT inhibits P-glycoprotein-mediated MDR by JNK 
activation in R-HepG2 cells
The activation of Mitogen-Activated Protein Kinase
(MAPK) enzyme JNK is recently suggested to be involved
in the down-regulation of P-glycoprotein [24]. Interest-
ingly, we revealed that the expression of P-glycoprotein
was down regulated dose-dependently in R-HepG2 cells
at 2 h after Pa-PDT treatment (Figure 4A), with induction
of phosphorylated JNK and down-regulation of a PDT-
resistant protein p-Erk when compared to the control that
was treated with 0.4 μM Pa alone as a dark control of the
experiment. This finding was confirmed by the increase in
the intracellular level of the P-glycoprotein substrate dox-
orubicin, which is a commonly used anti-cancer agent in
Pa-PDT inhibits p-glycoprotein mediated MDR in R-HepG2 cells Figure 4
Pa-PDT inhibits p-glycoprotein mediated MDR in R-HepG2 cells. (A) Differential expression of MDR proteins in Pa-
PDT treated R-HepG2 cells. Cells (3 × 106) were treated with Pa alone (0.4 μM Pa without PDT) or (0.4 μM, 0.6 μM, or 0.8 
μM) Pa for 2 h and then with light illumination (84 J/cm2) for 20 min. Cells were collected at 2 h after PDT treatment, then cell 
lysates were analyzed using Western blotting. The protein expression levels were semi-quantified and shown as relative inten-
sities normalized with the band intensity of the housekeeping β-actin in each sample. Representative results from a single 
experiment are shown from 5 independent experiments.(B) For the intracellular accumulation of Dox, cells (4 × 105/well) 
were treated with 0.04% ethanol (CTL, black solid), 0.6 μM (black line) and 0.8 μM (gray line) of Pa-PDT, and then the culture 
medium was changed to 4 μM Dox and further incubated for 2 h at 37°C, 5% CO2. The cells were collected and the intensity 
of Dox fluorescence was measured by a flow cytometer. (C) For detection of P-glycoprotein activity, R-HepG2 cells (1 × 104/
well) were pre-incubated with 0.04% ethanol (solvent control), 0.6 μM Pa (dark control), 0.6 μM Pa-PDT, or 0.6 μM Pa-PDT 
with 0.5 μM JNK inhibitor in a 6-well plate for 2 h and then the samples were illuminated with PDT. The treated cells were 
stained with 10 μM Rh-123 for 2 h at 37°C, 5% CO2 and then incubated with 5 μg/ml PI for further 15 min at room tempera-
ture. The cells were collected and analyzed by a flow cytometer, where the lower right quadrant (Rh-123 positive and PI nega-
tive) represents the cells that have intact plasma membrane but with down-regulated P-glycoprotein activity. The figure is a 
representative of 5 experiments and the results shown as mean ± SD.
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clinic, in R-HepG2 cells treated with 0.6 μM and 0.8 μM
Pa-PDT at 2 h (Figure 4B). In addition, co-staining of P-
glycoprotein substrate Rh-123 and PI was performed, in
order to rule out the possibility that the increase of mem-
brane permeability for the substrate was due to cell death.
According to our findings, Pa-PDT treatment could sup-
press the P-glycoprotein activity in a dose-dependent
manner (Figure 4C), as the intensity of Rh-123 in the R-
HepG2 cells with intact membrane (PI negative) was
increased in a dose-dependent manner from 2.0% (sol-
vent control) and 2.3% (dark control) to 68.4% in the
cells treated with 0.6 μM Pa-PDT. In addition, the Pa-PDT
mediated inhibition on P-glycoprotein was reversed by
JNK inhibitor, as the intensity of Rh-123 was found to be
42.7% in 0.6 μM Pa-PDT treated R-HepG2 cells in the
presence of JNK inhibitor (Figure 4C). Thus, Pa treatment
is able to inhibit the P-glycoprotein mediated MDR via
JNK activation when PDT illumination was applied in R-
HepG2 cells.
Pa-PDT triggers cell-death via mitochondrial apoptotic 
pathway in R-HepG2 cells
Apoptosis can be initiated by JNK that triggers the intrin-
sic (mitochondrial-dependent) pathways which result in
DNA fragmentation. According to results in Figure 5A,
phosphorylation of JNK was observed at 30 min after Pa-
PDT treatment, where the native form of JNK was slightly
decreased. The Pa-PDT induced p-JNK caused down-regu-
lation of the pro-apoptotic protein bcl-2 that facilitates
the collapse of mitochondrial membrane and eventually
initiates the intrinsic apoptotic pathway. Our results sup-
port this notion where both procaspase-9 and the active
caspase-9 were significantly increased in the Pa-PDT
treated R-HepG2 cells, and finally trigger the activation of
procaspase-3 that was started to be cleaved at 2 h after the
Pa-PDT treatment (Figure 5A). The involvement of JNK-
mediated intrinsic apoptotic pathway was confirmed by
the change of mitochondrial membrane potential in Pa-
PDT treated R-HepG2 cells. The cell population with
depolarized mitochondrial membrane was increased
dose-dependently from 5.2% to 83.8% in 0.8 μM Pa-PDT
treated cells; however, such collapse was partially inhib-
ited in the presence of JNK inhibitor (Figure 5B). Our
finding demonstrated that the Pa-PDT mediated death of
R-HepG2 cells is a result of the activation of JNK that ini-
tiates the mitochondrial-mediated apoptotic pathway.
Discussion
MDR is a frequent phenomenon in human liver cancers
with prolonged chemotherapy treatment. Hepatoma cells
with MDR property are able to tolerate a number of anti-
tumor agents [25]. Although using an increasing dosage of
drugs may overcome MDR, the side effects of drugs usu-
ally shorten the life period of patients. PDT is a potential
method to overcome MDR [18-22], which relies on a syn-
ergistic effect of two non-toxic elements, photosensitizer
and light irradiation [3,4].
The anti-tumor effects of Pa-PDT were reported in skin
cancer and hepatoma in vitro [23,26]. However, its thera-
peutic potential in killing human liver cancer especially
those with MDR is not fully investigated. A reduction of
intracellular drug concentration in tumor cells with MDR
is a common phenomenon for the anti-cancer agents that
belong to the P-glycoprotein substrate family. This mech-
anism decreases the drug effect and drug sensitivity in
patients during chemotherapy [25]. According to the
results shown in Figure 1A, the cellular uptake levels of 2
μM Pa in both HepG2 and R-HepG2 cells were similar,
whereas a reduction was observed in the case of 2 μM Dox
in R-HepG2 cells as a result of P-glycoprotein overexpres-
sion. This result is consistent with our previous finding
where higher concentrations of drugs, nearly 20 μM Pa
and 8 μM Dox were applied and the drugs uptake levels
were monitored by flow cytometry [27]. In addition, the
cytotoxicity of Pa-PDT was measured in human hepatoma
cells HepG2 and its MDR line R-HepG2. As shown in Fig-
ure 1B, Pa-PDT could circumvent the MDR of R-HepG2
cells and killed the cells with an IC50 value of 0.6 μM,
only 1.5-fold higher than that of its parental cell line (data
not shown). The high degree of cytotoxicity in R-HepG2
cells might be a result of the alternations in the apoptotic
mechanism that render the cells more sensitive to Pa-PDT
[28]. In addition, our results demonstrate that the cytotox-
icity of Pa was rapidly increased when light illumination
was applied. For example, the IC50 value of Pa was dra-
matically decreased from 25 μM (from our previous
study) to 0.6 μM at 24 h after the PDT treatment in R-
HepG2 cells (Figure 1B) [27]. Pa shares the same charac-
teristics with other photosensitizers in that no cell death
was induced when cells are treated with light illumination
or Pa (at concentrations below 2 μM) alone, this property
would minimize the undesirable side effects towards nor-
mal tissues during anti-tumor treatments. To show the
therapeutic potential of Pa-PDT in hepatoma cells with
MDR, in vivo study was performed. Our results illustrate
that Pa-PDT could significantly (p < 0.05) inhibit the
growth of R-HepG2 cells in the tested group with insignif-
icant damages towards the heart and liver of the hosts
when compared to that of the control in which only Pa
was injected and no light irradiation was applied (Figure
1C and 1D). The level of ALT was decreased in the Pa-PDT
treated group. Pa is an active component of a traditional
Chinese medicine S. barbata that is commonly used for
treating liver disease, our finding thus suggests a potential
beneficial effect of Pa-PDT on liver protection and further
study should be conducted to confirm this idea [11]. Nev-
ertheless, our previous study showed that Pa-PDT is less
cytotoxic in the human normal hepatic cell line WRL-68
in vitro, and in vivo study reported the short retention of PaMolecular Cancer 2009, 8:56 http://www.molecular-cancer.com/content/8/1/56
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in normal tissues as HDL and LDL can significantly pro-
mote the efflux of Pa from normal cells [12,29].
The mechanism of Pa-PDT mediated anti-proliferative
effect in R-HepG2 cells was investigated in the present
work. Apoptosis is important for tissue homeostasis and
cell death. Our previous study demonstrated that Pa
induced cell cycle arrest in R-HepG2 cells when no light
illumination was applied [27]. Our present results suggest
that PDT treatment could render Pa to become an apopto-
sis inducer for R-HepG2 cells as evidenced by the follow-
ing observations: DNA fragmentation, a hallmark
phenomenon of apoptosis [30], was only detected in Pa-
treated samples with light illumination (Figure 2A); and
the level of PS externalization (Figure 2B) were dramati-
cally increased in the Pa-PDT treated R-HepG2 cells.
Many proteins are involved in the apoptosis induction
and execution processes [4,31,32]. For example, activa-
tion of caspase cascade is one of the major effectors for
promoting apoptosis. Our observation showed that the
fluorescence of Pa was distributed only in cytoplasm but
not in nuclei indicating that Pa largely acts on the intrinsic
apoptotic pathway (Figure 1A). To support this notion,
Pa-PDT activates JNK-mediated apoptosis in R-HepG2 cells Figure 5
Pa-PDT activates JNK-mediated apoptosis in R-HepG2 cells. (A) Changes in apoptosis regulatory proteins in Pa-PDT 
treated R-HepG2 cells. Cells (3 × 106) were treated with solvent (0.04% ethanol (CTL)) or 0.6 μM Pa-PDT, and collected at 
appropriate time points, where solvent control was collected at 30 min after the treatment. The cell lysates were prepared and 
the changes in the level of various apoptosis-related proteins were analyzed using Western blotting. The protein expression 
levels were semi-quantified and shown as relative intensities normalized with the band intensity of the housekeeping β-actin in 
each sample. Representative results from a single experiment are shown from 5 independent experiments.(B) To determinate 
the effect of Pa-PDT on Δψm, flow cytometry analysis was conducted in R-HepG2 cells (3 × 105/well) 1 h after light illumina-
tion (84 J/cm2, 20 min) with 0.6 μM Pa, 0.8 μM Pa, or 0.8 μM Pa with 0.5 μM JNK inhibitor. The cells were then stained with 
JC-1 (10 μM) for 15 min. The green and red fluorescence of JC-1 were acquired subsequently with a flow cytometer, and the 
results shown as mean ± SD of 3 independent experiments.
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our results clearly demonstrated that the active form of
caspase-9 was increased and the precursor of caspase-3
was cleaved significantly after Pa-PDT treatment (Figure
5A). It implies that the mitochondrial apoptotic pathway
might be activated by Pa-PDT treatment in R-HepG2 cells.
Putting all our results together, it seems likely that the acti-
vated caspase-9 acted on pro-caspase-3 and the activated
caspase-3 cleaved PARP to prevent DNA repair and trigger
the chromosomal DNA fragmentation in R-HepG2 cells,
leading to cell death.
To explain the involvement of mitochondria in the mech-
anism of Pa-PDT, we hypothesized that Pa works like
other photosensitizers which can cause damages of mito-
chondria in tumor cells after PDT [24]. In fact, the intrac-
ellular singlet oxygen concentration increased in R-
HepG2 cells after Pa-PDT (Figure 3A) and this increase
may be due to mitochondrial damage. Intracellular loca-
tion of the photosensitizer could affect the efficiency of
the killing effect. In our previous study, we have demon-
strated that Pa was localized to the mitochondria in the
treated cells to elicit the photodamage [12,13]. In this
study, our data further confirm this finding, as a collapse
of the mitochondria membrane potential was detected by
the JC-1 assay (Figure 5B). In addition, the decrease in the
level of the anti-apoptotic protein bcl-2 would also elicit
more mitochondrial injuries (Figure 5A) which facilitate
the release of mitochondrial singlet oxygen to the cytosol
and lead to the rapid increase of intracellular singlet oxy-
gen concentration in Pa-PDT treated cells (Figure 3A).
Therefore, our observations support the principle that
photosensitizers, including Pa, can cause damage of mito-
chondria of tumor cells after PDT, and this triggers cell
death pathways, including the release of singlet oxygen,
etc., in the treated tumor cells [4].
A number of proteins respond to the internal induced
stresses. One example is the MAPK kinase JNK, which is
found to be activated after Pa-PDT treatment (Figure 5A).
Application of JNK inhibitor on Pa-PDT treated R-HepG2
cells would suppress the induction of apoptosis and shift
the cells to undergo cell-cycle arrest at G2/M phase (Figure
3C). The Pa-PDT induced apoptosis is started by the col-
lapse of mitochondria which is facilitated by JNK, accord-
ing to Figure 4B, the degree of mitochondrial membrane
potential change was reduced significantly when activa-
tion of JNK was inhibited. Our results showed that Pa-
PDT suppresses the proliferation of R-HepG2 cells by acti-
vating the JNK-mediated intrinsic apoptotic pathway.
In addition, the activated JNK (p-JNK) would inhibit the
expression of P-glycoprotein and result in the suppression
of MDR property on the cancer cells [24,33]. PDT is
recently reported to reduce the expression of P-glycopro-
tein in cancer cells, however, the linkage of JNK pathway
and PDT-induced down-regulation of P-glycoprotein is
not yet investigated [34]. The expression of P-glycoprotein
was significantly decreased after Pa-PDT treatment (Figure
4A) and led to a decreased refluxing of the P-glycoprotein
substrates Dox and Rh-123 in R-HepG2 cells (Figure 4B
and 4C). Such inhibition can be suppressed by co-incu-
bating with JNK inhibitor (Figure 4C). Although our pre-
vious study reported that 20 μM Pa alone (without light
illumination) can also inhibit the P-glycoprotein expres-
sion in R-HepG2 cells, the response time is much longer
(24h-incubation with Pa alone) and the mechanism is
due to the regulation of MDR1 expression on transcrip-
tional level instead of the activation of JNK [28]. Further-
more, we showed that the activation of Erk, responsible
for the resistance to PDT, was suppressed in the Pa-PDT
treated R-HepG2 cells (Figure 4A); it implied that using Pa
as a photosensitizer will not induce resistance to the pho-
todynamic treatment [35]. Taken together, our findings
provide the first evidence that Pa-PDT would decrease the
P-glycoprotein level via JNK-mediated pathway, and
result in an enhancement of intracellular Dox level in
MDR human liver tumor cells which would overcome the
difficulty in clinical situation.
Materials and methods
Materials
Culture media were purchased from Invitrogen (USA). All
other chemicals were purchased from Sigma Chemical Co
(USA). Pa originally purified from Scutellaria barbata [11]
is now commercially available. Pa used in this study was
purchased from Frontier Scientific (USA), and JNK inhib-
itor (JNK inhibitor II) was purchased from Merck (USA).
Cell cultures
HepG2 cells obtained from American Type Culture Col-
lection (ATCC) were cultured in RPMI-1640 medium with
10% (v/v) fetal bovine serum (FBS), 100 U/ml penicillin
G and 100 μg/ml streptomycin. Cells were incubated at
37°C in a humidified atmosphere of air/CO2 (95%: 5%).
For the development of MDR cells, HepG2 cells were cul-
tured with Dox from 0.1 to 100 μM during cell passages.
After several rounds of selection, R-HepG2 with MDR
properties was obtained. R-HepG2 was developed in our
laboratory and characterized with an overexpression of P-
glycoprotein [6,24]. R-HepG2 cells were then cultured
with 1.2 μM Dox to maintain its MDR properties [25].
Measurement of drug accumulation
The method described earlier was used [25]. Cells (3 ×
105/well) grown on the coverslips were preloaded with 2
μM Pa or 2 μM Dox and incubated at 37°C in a humidi-
fied atmosphere of air/CO2 (95%: 5%) for 2 h without
PDT treatment. After washing 3 times with PBS, fluores-
cence of Pa or Dox was observed under a Nikon TE2000Molecular Cancer 2009, 8:56 http://www.molecular-cancer.com/content/8/1/56
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fluorescence microscope with an excitation wavelength at
578 nm and an emission wavelength at 610 nm.
Pa-mediated photodynamic therapy (Pa-PDT) on cancer 
cells
Cells were seeded in culture plate and incubated for 24 h
to allow attachment. After washing with phosphate buff-
ered saline (PBS), the cells were pre-incubated with appro-
priate concentrations of Pa for 2 h. Then the cells were
photo-irradiated for 20 min using a 600 W quartz-halo-
gen lamp with a long pass filter at 610 nm, and the light
intensity was 70 mW/cm2(i.e. 20 min of irradiation = 84
J/cm2) [13].
Measurement of cell viability
Twenty-four hours after Pa-PDT treatment, the cells were
washed gently with PBS. Thirty microliters of methyl-thi-
azoldiphenyl tetrazolium (MTT) (5 mg/ml) was added to
each well and incubated for 2 h at 37°C. The MTT solu-
tion was then replaced by 100 μl of dimethyl sulfoxide in
each well. Absorbance was measured with a microtitre-
plate reader (Bio-Rad) at 540 nm and all data were calcu-
lated as percentage of control.
In vivo study of Pa-PDT on R-HepG2 cells bearing nude 
mice
The method described earlier was used with slight modi-
fications [12]. Male 4–6 weeks old nude mice were sup-
plied by the Laboratory Animal Services Center of The
Chinese University of Hong Kong. The care and use of the
animals were in compliance with institutional guidelines.
R-HepG2 cells (1 × 107) were inoculated at the back of
nude mice. After one week of tumor growth (tumor size
about 150 mm3), 16 mice were randomly divided into
treatment and control groups. Both groups received 300
μg/kg Pa by local injection (s.c.) nearby the transplanted
tumor site only once. After 24 h, one photo-activation
(126 J/cm2) was applied to whole animal for 30 min in
the treatment group. After 10 days, the tumor volume of
each subject was determined by caliper measurements
(mm) according to the following formula: Volume (mm3)
= (Length × Width × Height) π/2. The data were calculated
as percentage of control.
Assessment on damages of heart and liver
Blood samples of each tumor bearing nude mouse were
collected in heparin-coated tubes at the end of the treat-
ment. After centrifugation at 1500 × g for 5 min at 4°C,
the plasma was collected and stored at 4°C for enzyme
assays. Lactate dehydrogenase (LDH), aspartate ami-
notransaminase (AST) and alanine aminotransaminase
(ALT) activities were determined by using Stanbio LDH
Liqui-UV® kit (Stanbio Laboratory), Infinity™ AST reagent
and Infinity™ ALT reagent (Thermo Electron Corporation)
respectively. All enzyme assays were carried out at 37°C in
a UV1601 spectrophotometer with a TCC-240A tempera-
ture controller (Shimadzu Ltd.).
DNA fragmentation detection
The Pa- or solvent-treated cells (2 × 106/dish) were
washed twice with PBS 24 h after PDT as in our previous
study [12]. The cells were then resuspended in 400 μl of
DNA lysis buffer (200 mM Tris-HCl, 100 mM EDTA, 1%
SDS, pH 8.3). The mixture was vortexed vigorously and 20
μl of proteinase K (10 mg/ml) was added. After 2 h of
incubation at 37°C, 150 μl of saturated sodium chloride
solution was added and mixed completely. The samples
were centrifuged at 6500 × g for 15 min at 4°C. Superna-
tant was collected, mixed with 1 ml of cold ethanol and
then centrifuged again at 15000 × g for 20 min. The pellets
were washed with 1 ml of cold 75% ethanol, centrifuged
at 15000 × g for 20 min and allowed to dry. Twenty micro-
liters of ribonuclease A (RNase A) (0.2 mg/ml) was added
to the dry pellet and incubation was allowed at 37°C for
90 min. The pattern of genomic DNA extract was visual-
ized by electrophoresis in 1.2% agarose gel containing
ethidium bromide and photographed under UV light.
Detection of phosphatidylserine (PS) translocation
To detect the translocation of PS, an annexin V-FITC kit
(Trevigen) was used. The cells (4 × 105/well) were stained
with 100 μl of staining reagent at room temperature for 15
min in dark according to our previous study [13]. Then
the samples were mixed with 400 μl of 1× binding buffer
and analyzed by FACSort flow cytometry (Becton Dickin-
son) with the CellQuest software. The cell population was
gated by FSC and SSC. The fluorescence signals were
acquired by FL1 and FL3 channel in log scale, and no
influence of Pa fluorescence was detected when its con-
centration is lower than 2 μM.
Detection of intracellular singlet oxygen after Pa-PDT
The assay was performed in a 96-well culture plate con-
taining 2 × 104 cells in each well. The cells were gently
rinsed with PBS at 10 min after PDT, and 30 μl of 10 μM
trans-1-(2'-methoxyvinyl) pyrene was added to each well
and incubated in dark for 15 min at 37°C. Then, the stain-
ing solution in the well was replaced by 50 μl PBS, and the
intensities of fluorescence were acquired by a FLUOstar
Galaxy plate reader (BMG Labtech).
Cell cycle analysis
This assay was performed according to the procedures as
described in [27]. Cells (3 × 105/well) were seeded in a 6-
well plate and incubated for 24 h to allow attachment.
Twenty-four hours after photodynamic treatment, the
cells were washed twice with PBS and fixed in 70% etha-
nol overnight at 4°C. Then the cells were resupended in
PBS containing propidium iodide (PI) (10 μg/ml) andMolecular Cancer 2009, 8:56 http://www.molecular-cancer.com/content/8/1/56
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RNase A (50 μg/ml). The samples were then analyzed by
a FACSort flow cytometer (Becton Dickinson).
Western blot analysis
The method described earlier was used [36]. The PDT-
treated cells (3 × 106 cells/plate) collected at appropriate
time after PDT were lysed by incubating the cells in the
whole cell extraction buffer (2% sodium dodecyl sufate
(SDS), 10% glycerol, 625 mM Tris-HCl (pH 6.8), β-mer-
captoethanol (5% v/v)) for 2 h at 4°C. Samples were
boiled in water for 10 min, and then centrifuged at 11000
× g for 20 min at 4°C. The supernatant proteins were
resolved by 12.5% SDS polyacrylamide gel and trans-
ferred to 0.45 μm polyvinylidene fluoride (PVDF) mem-
brane (Immobilon, Millipore). The membrane was
blocked with 10% non-fat milk in Tris buffered saline
containing Tween-20 (TBS-T) (20 mM Tris-HCl (pH 7.6),
150 mM NaCl, 0.1% Tween-20) and then incubated with
primary human antibodies against β-actin (Sigma), Bcl-2,
JNK, p-JNK, p-ERK, procaspase-3 (Santa Cruz), caspase-9
(Stressgen), and P-glycoprotein (Merck) in TBS-T. After
incubation with the secondary antibody conjugated with
horseradish peroxidase, immunodetected proteins were
visualized by using an enhanced chemiluminescence
assay kit (Amersham Life Science). The protein content of
each sample was normalized by the corresponding β-
actin.
Detection of P-glycoprotein activity
The Pa-PDT treated cells (3 × 105/well) on a 6-well plate
were incubated with 10 μM Rh-123 following photody-
namic treatment. After 2h-incubation at 37°C, the cells
were collected and washed twice with PBS, and then resu-
pended in PBS containing PI (5 μg/ml) for 15 min at
room temperature. The samples were finally analyzed by
the FACSort flow cytometer (Becton Dickinson).
Detection of changes in mitochondrial membrane 
potential (Δψm)
Cells (3 × 105/well) were seeded to a 6-well culture plate
and photodynamically treated on the next day. The cells
were collected and washed twice with PBS 1 h after PDT,
and then stained with 10 μg/ml JC-1 with a supplement of
20 μM verapamil for 15 min at 37°C. Then the cells were
analyzed by FACSort flow cytometry with the CellQuest
software (Becton Dickinson). The cell population was
gated by FSC and SSC. The signal was detected by FL1 and
FL3 channels for JC-1 in log scale, where no influence of
Pa fluorescence was detected when its concentration is
lower than 2 μM.
Statistical analysis
Data were presented as mean ± S.D. of various experi-
ments. Statistical analysis was performed by one-way
analysis of variance (ANOVA) with Bonferroni post-hoc
test (two-tailed). P < 0.05 was considered statistically sig-
nificant.
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